 |
Vol.59 No.1 contents | Japanese/English |
 | Full Text of PDF (2570K) Article in Japanese |
- Case Report -
A Case of Lung Cancer with Peritoneal Carcinomatosis Effectively Treated with Docetaxel
Kenji Morimoto1, Koji Date1, Hidehiko Kawano11Department of Pulmonary Medicine, Kyoto Chubu Medical Center, Japan
Background. Peritoneal carcinomatosis (PC) is a rare complication of lung cancer. Although several case reports have noted that epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment was effective in the treatment of PC in patients with EGFR-positive lung cancer, few case reports have documented the successful treatment of driver mutation-negative lung cancer. Case. A 76-year-old man presented with dyspnea on exertion. He was diagnosed with stage IVB driver mutation-negative lung adenocarcinoma and received chemotherapy with cisplatin, pemetrexed, and bevacizumab as a first-line treatment followed by maintenance therapy with pemetrexed and bevacizumab. At one year and four months after the initiation of chemotherapy, abdominal computed tomography showed ascites and peritoneal thickening. A relapse of lung adenocarcinoma was diagnosed based on the presence of abdominal paracentesis. He was treated with pembrolizumab as a second-line therapy; however, his ascites increased. He received treatment with docetaxel as a third-line therapy and achieved stable disease. Conclusion. If a patient's performance status is good, docetaxel might be effective for the treatment of PC as a complication of relapsed lung cancer.
key words: Peritoneal carcinomatosis, Lung cancer, Docetaxel
Received: October 9, 2018
Accepted: November 24, 2018
JJLC 59 (1): 71-75, 2019
